The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries hurt global stock ...

Sanofi (NASDAQ: SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Berenberg Bank analyst Luisa Hector ...

On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results from the open-label Phase 4 ...

After 25 years developing vaccines with French drugmaker Sanofi, Sanjay Gurunathan, M.D., has departed for GSK. Gurunathan ...

Lina Nielsen has vowed to spend the rest of her life campaigning for greater awareness of multiple sclerosis after speaking ...

AI digital transformation is reshaping work. Andrew Kilshaw shares why this shift is unique and how leaders can drive real ...

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.

Seven of those fired had received up to US$55,000 from drugmakers. Read more at straitstimes.com. Read more at ...

SpliceBio has closed a Series B financing round, raising $135m for the clinical development of SB-007 for Stargardt disease.

STOCKHOLM--Swedish buyout group EQT and French pharmaceutical major Sanofi co-led a $135 million series B financing round in Spanish biotech company SpliceBio. EQT co-led the funding round with Sanofi ...